Clinical trial · no report yet · Phase 1/Phase 2
NCT06741644
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
- NCT06741644 ↗
- Recruiting
- CStone Pharmaceuticals
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 5 |
The trial
ClinicalTrials.gov- Official title
- A Phase I/II, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS2009, a Tri-specific Antibody Targeting PD-1/VEGFA/CTLA-4, as Monotherapy and Combination Therapy in Participants With Advanced Solid Tumors
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- Advanced Solid Tumors
- Interventions
- CS2009; CS2009; Pemetrexed; Carboplatin; Paclitaxel; Etoposide; Nab-paclitaxel; Oxaliplatin; Capecitabine; Docetaxel; Leucovorin; 5-FU; Cisplatin; Gemcitabine; Irinotecan
- Arms
- Dose Escalation · Experimental
- Dose Expansion · Experimental
- Enrollment
- 800 (estimated)
- Primary outcomes
- [Dose Escalation] Maximum tolerated dose (MTD) of CS2009
- [Dose Escalation] Tentative recommended Phase II dose (RP2D) of CS2009
- [Dose Escalation] Number of participants with adverse events (AEs)
- [Dose Expansion] Objective response rate (ORR) evaluated by investigators per RECIST v1.1
- Sponsor
- CStone Pharmaceuticals
- Start
- Feb 24, 2025
- Primary completion
- Jan 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06741644 · updated Aug 20, 2026